Colorectal Cancers
Multitargeted The Plenary Program will include Faculty whose Participation has been confirmed at press time.
ACCREDITATION
The Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit designation
The Certification of Attendance will be provided to all professionals.
FACULTY DISCLOSURE POLICY
It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency and scientific rigor in all CME sponsored educational activities. All faculty participating in the planning or implementation of a supported activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict-of-interest that may arise from the situation. Presenters must also make a meaningful disclosure to the audience in their discussions of unlabeled or unapproved drugs or devices. No CME is issued to physicians for the Saturday session.
CONTACT INFORMATION

ReFUnd POliCY
A 10% Administrative Charge plus a $15 processing fee will be deducted from all refunds issued. REQUESTS FOR REFUNDS RECEIVED AFTER Nov. 1 will not be honored by the Post Graduate School of Mount Sinai.
HOTELS
The MARRIOTT MARQUIS HOTEL located on Broadway between 45th and 46th
Streets in midtown Manhattan is the Headquarters Hotel and Symposium site.
Blocks of rooms at special conference rates have been set aside for symposium attendees at the Marriott and the Millennium Hotels. 
PROGRAM GOALS
The extensive scope and intensive coverage of new developments in cancer therapeutics at this annual educational activity provide cancer care providers with the opportunity to learn about the new agents, new modalities, clinical trials and emerging developments that will result in continuing progress in the control and cure of cancer.
LEARNING OBJECTIVES
At the conclusion of the program, participants should be able to:
1. Evaluate the potential benefits of the emerging developments in cancer therapy.
2. Employ new concepts, agents and regimens in cancer patient management to achieve better outcomes.
3. Inform patients of improved treatment options and the benefits of enrollment in clinical trials. 
TARGET AUDIENCE
